Navigation Links
ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/6/2011

IRVINE, Calif., Sept. 6, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) announced today that its Chief Executive Officer, Frank L. Jaksch, Jr., will be presenting the company's business strategy and growth opportunities at the 2011 Rodman & Renshaw Annual Global Investment Conference. The event will be held September 11-13, 2011 at the Waldorf Astoria in New York City.

ChromaDex is scheduled to make its presentation on Tuesday, September 13th at 11:30 a.m. local time. The company's presentation is currently available on its website, www.chromadex.com. For further details about the conference, please visit http://www.rodmanandrenshaw.com/conferences?id=162.

For more information about ChromaDex Corporation, visit www.chromadex.com and www.pteropure.com.

About ChromaDex®

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

ChromaDex Contact
Laura Carney
Administrative Assistant
949-419-0288
laurac@chromadex.com

ChromaDex Media Inquiries:
Chandler Chicco Agency
Kerry Sinclair, Media Specialist
310-309-1031
ksinclair@ccapr.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex Announces 2008 Year End Financial Results
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
5. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
6. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
7. InterMune to Present at Canaccord Adams Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... engineers, and scientists from around the world, was today awarded the "Best Science ... is based entirely on merit and decided upon by a dedicated team of ...
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, ... market is expected to reach USD 739.9 Million by 2021 from USD 557.1 ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):